Clinical Data Presented at SIR Meeting Indicates New Catheter-based Treatment Could Soon Become the Standard of Care for Treating Acute DVT
WASHINGTON, March 19 /PRNewswire/ -- Registry clinical data presented this week at the Society of Interventional Radiology's 33rd Annual Scientific Meeting shows DVT treatment with the Trellis(R) Peripheral Infusion System from Bacchus Vascular, Inc. (Santa Clara, CA) successfully breaks up the blood clot in most patients in about 20 minutes.
This technique restores blood flow more quickly and safely than current catheter-directed thrombolysis (CDT) techniques. It provides an important adjunct to the standard therapy of anti-coagulation alone, which is intended to prevent future clots but does not break up the existing clot.
Gerard O'Sullivan, MD, Interventional Radiologist from University Hospital in Galway, Ireland, reported the latest outcomes from the manufacturer's registry of clinical results of the Trellis catheter at over 360 hospitals in the U.S. and internationally.
In a total of 827 limbs treated in 771 patients, Grade II and III lysis with restoration of patency in patients with acute clot was achieved in 97% of cases. The vast majority of cases (> 80%) were completed in less than two hours in the single-setting of the interventional suite, and the usage of the Trellis catheter itself was typically around 20 minutes. Although required with CDT procedures, no follow-up monitoring in a costly critical care unit was typically needed with the Trellis catheter treatment.
There were no reported bleeding complications from the Trellis procedure in acute follow up and compared to CDT the dosage of thrombolytic drugs such as t-PA are appreciably reduced with use of the Trellis device.
"The single biggest change in treating DVT patients with the Trellis catheter is our ability to get the clot out and have the patients able to walk away immediately after the procedure," said Dr. O'Sullivan. "Literally, the patient comes into the procedure with difficulty or cannot walk and I can now walk them out of the procedure room at the end of the treatment. These patients are typically back to work in 2-3 days versus the 6-8 weeks with anticoagulation-only treatment."
About Bacchus Vascular
Bacchus Vascular, Inc. is a privately held medical device company dedicated to the treatment of peripheral vascular disease. Dr. Thomas Fogarty, a noted inventor and cardiovascular surgeon, founded the company with the vision of transforming blood clot removal from peripheral blood vessels into a fast, simple, minimally-invasive catheter-based procedure. Thousands of patients suffering from DVT and other occlusive vascular diseases have been treated worldwide to date using the company's Trellis(R) Peripheral Infusion System and other products.
For more information, visit http://www.bacchusvascular.com
|SOURCE Bacchus Vascular, Inc.|
Copyright©2008 PR Newswire.
All rights reserved